Topical treatment for burn pain by blocking cutaneous pain receptors.

Project Summary (Abstract) Title: Technical and Business Assistance for Commercialization of Topical Treatment for Burn Pain This TABA request supports critical commercialization activities for the Phase I SBIR project. The project focuses on the development of a first-in-class, non-opioid topical formulation targeting TRPV1 and related cutaneous pain receptors, offering a novel therapeutic approach for managing burn pain. This support will directly enhance our readiness for Phase II funding and facilitate downstream partnering or licensing opportunities. The proposed assistance is essential to translating our research into a viable therapeutic product that addresses the significant unmet need in treating burn-related pain.